GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0042730 | Liver | NAFLD | fibrinolysis | 15/1882 | 25/18723 | 1.26e-09 | 2.30e-07 | 15 |
GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
GO:0050819 | Liver | NAFLD | negative regulation of coagulation | 21/1882 | 53/18723 | 1.33e-08 | 1.69e-06 | 21 |
GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
GO:0061045 | Liver | NAFLD | negative regulation of wound healing | 26/1882 | 78/18723 | 1.86e-08 | 2.09e-06 | 26 |
GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
GO:0051917 | Liver | NAFLD | regulation of fibrinolysis | 10/1882 | 14/18723 | 7.05e-08 | 6.34e-06 | 10 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00108107 | Liver | NAFLD | regulation of cell-substrate adhesion | 47/1882 | 221/18723 | 5.30e-07 | 3.16e-05 | 47 |
GO:00903035 | Liver | NAFLD | positive regulation of wound healing | 20/1882 | 59/18723 | 5.91e-07 | 3.46e-05 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLG | SNV | Missense_Mutation | novel | c.871N>T | p.Val291Leu | p.V291L | P00747 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-3C-AAAU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | zoladex | SD |
PLG | SNV | Missense_Mutation | novel | c.1833N>C | p.Leu611Phe | p.L611F | P00747 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PLG | SNV | Missense_Mutation | novel | c.22C>A | p.Leu8Ile | p.L8I | P00747 | protein_coding | tolerated(0.05) | benign(0.368) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLG | SNV | Missense_Mutation | | c.1993N>C | p.Asp665His | p.D665H | P00747 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PLG | SNV | Missense_Mutation | novel | c.1670N>C | p.Val557Ala | p.V557A | P00747 | protein_coding | deleterious(0) | benign(0.411) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PLG | SNV | Missense_Mutation | novel | c.866T>G | p.Val289Gly | p.V289G | P00747 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLG | SNV | Missense_Mutation | | c.747N>A | p.Asp249Glu | p.D249E | P00747 | protein_coding | tolerated(0.05) | benign(0.167) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLG | SNV | Missense_Mutation | novel | c.866T>G | p.Val289Gly | p.V289G | P00747 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PLG | SNV | Missense_Mutation | | c.1078G>A | p.Glu360Lys | p.E360K | P00747 | protein_coding | tolerated(0.1) | benign(0.345) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PLG | SNV | Missense_Mutation | novel | c.288N>T | p.Lys96Asn | p.K96N | P00747 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-E2-A2P5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | UROKINASE | UROKINASE | |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | ALTEPLASE | ALTEPLASE | |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | ALTEPLASE | ALTEPLASE | |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | DESMOTEPLASE | DESMOTEPLASE | |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | Reteplase | RETEPLASE | |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | NYSTATIN | NYSTATIN | 7721938 |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | ANISTREPLASE | ANISTREPLASE | |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | RETEPLASE | RETEPLASE | |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | BORTEZOMIB | BORTEZOMIB | 20875739 |
5340 | PLG | DRUGGABLE GENOME, ENZYME, CELL SURFACE, PROTEASE | | ANTIDEPRESSANTS | | 16890384 |